德国拜耳利伐沙班在国内买的到吗？

(Rivaroxaban) has a rapid onset of action orally, which not only avoids the problems of slow onset of action and early procoagulation of warfarin, but also avoids the risks of complications and prolonged hospitalization associated with subcutaneous injection of low molecular weight heparin. Moreover, research on rivaroxaban combined with catheter thrombolysis in the treatment of acute lower extremity venous thrombosis showed that rivaroxaban combined with catheter thrombolysis in the treatment of acute lower extremity deep vein thrombosis is effective, can significantly inhibit the body's inflammatory response, improve the patient's coagulation function, and has a good prognosis. So, is Bayer Rivaroxaban from Germany available in the country?

Germany's Bayer Rivaroxaban was approved to be marketed in China in June 2009 under the trade name Xarelto. From then on, patients could purchase the medicines they needed without going abroad. In addition to purchasing German Bayer Rivaroxaban in China, patients can also obtain drug purchase channels overseas through some formal and reliable overseas medical service organizations in China (such as Medical Companion Travel). It is understood that rivaroxaban produced by Bayer in Germany is available in two specifications, with roughly the same price, both around $400.

The success of Bayer Healthcare, a multinational pharmaceutical company, is attributed to its R&D-led corporate development strategy. Its R&D of prescription drugs involves oral hypoglycemic drugs, women's health products, hormone replacement therapy, imaging diagnosis, and oncology drugs. Over the years, the quality of its drugs has been recognized by the world, its brand reputation has been improved, and its corporate scale has gradually grown, and a new round of development has begun around R&D. Even if Bayer Healthcare starts to get involved in the field of over-the-counter drugs and plans to get involved in the field of traditional Chinese medicine, its R&D experience and energy will help improve over-the-counter drugs and traditional Chinese medicine to a certain extent. Therefore, Bayer Healthcare’s position with R&D as its core competitiveness will be difficult to shake in a short period of time.

The product developed and produced by Bayer in Germany also has a relatively broad market prospect and has become an important treatment choice for many patients with venous thrombosis. Patients can purchase and use it with confidence.

Recommended hot articles: /newsDetail/86347.html